Cory Perla

SAN DIEGO —In this video, Jennifer A. Woyach, MD, discusses results from the AMPLIFY trial, presented at ASH Annual Meeting and Exhibition.The trial evaluated fixed-duration acalabrutinib (Calquence, AstraZeneca) plus venetoclax (Venclexta, AbbVie) with or without obinutuzumab (Gazyva, Genentech) versus chemoimmunotherapy as front-line treatment for chronic lymphocytic leukemia.

CHICAGO — In this video, Clement K. Chan, MD, FACS, discusses highlights from the AAO meeting, including presentations on pegcetacoplan and avacincaptad pegol for the treatment of geographic atrophy.In addition, Chan, a retina specialist at Desert Retina Consultants, recaps a panel discussion during which experts shared their opinions on the use of these therapies for the treatment of GA.

CHICAGO —In this video, Karl G. Csaky, MD, PhD, highlights discussions from the AAO meeting on the adequacy of tools used to assess the effectiveness of treatments for dry age-related macular degeneration.

CHICAGO — In this video, Karl G. Csaky, MD, PhD, discusses highlights from the AAO annual meeting.In a panel discussion on dry age-related macular degeneration, experts debated the importance of anatomic vs. functional benefits of dry AMD therapies, according to Csaky, chief executive and medical officer of the Retina Foundation of the Southwest in Dallas.

CHICAGO — In this video, Joan W. Miller, MD, chair of ophthalmology at Mass Eye and Ear, discusses controversies surrounding the use of complement inhibitors for the treatment of geographic atrophy.

CHICAGO — In this video, Joan W. Miller, MD, chair of ophthalmology at Mass Eye and Ear, discusses highlights from the AAO meeting.

In this video, Barbara Blodi, MD, discusses results from the ARCHER trial presented at the American Society of Retina Specialists annual meeting.

In this video, Barbara Blodi, MD, discusses advancements in complement inhibition treatments for geographic atrophy.At the ASRS annual meeting, there were panel discussions about the pros and cons of these types of therapies, Blodi said.

In this video, Barbara Blodi, MD, discusses the importance of the ellipsoid zone as a biomarker in patients with geographic atrophy.“There are now AI systems that can measure the ellipsoid zone — its presence or absence or disruption,” Blodi said during a recap about presentations from the ASRS annual meeting.

In this video, Barbara Blodi, MD, discusses advancements in gene therapy for the treatment of age-related macular degeneration.At the ASRS annual meeting, several sessions revolved around gene therapy in clinical trials from various companies and delivery of the therapy.